Abstracts tagged "Rheumatoid arthritis (RA)"

Abstract Number: 2610 • 2015 ACR/ARHP Annual Meeting
Real-World Use of Tocilizumab in Rheumatoid Arthritis Patients: Cardiovascular Risk, Concomitant Treatment, and Outcomes over 6 Months of Follow-up
Boulos Haraoui¹, Shahin Jamal², Vandana Ahluwalia³, Tarang Manchanda⁴ and Majed M. Khraishi⁵, ¹Institut de Rhumatologie de Montréal and University of Montreal, Montreal, QC, Canada, ²Vancouver Coastal Health, Vancouver, BC, Canada, ³Brampton Civic Hospital, Brampton, ON, Canada, ⁴Hoffmann-La Roche Canada, Mississauga, ON, Canada, ⁵Nexus Clinical Research, St Johns, NF, Canada
Background/Purpose: Tocilizumab (TCZ) is approved for the treatment of adults with rheumatoid arthritis (RA) either as monotherapy or in combination with disease-modifying antirheumatic drugs (DMARDs).…
Abstract Number: 567 • 2015 ACR/ARHP Annual Meeting
Rituximab Associated Late Onset Neutropenia – a Rheumatology Case Series and Review of the Literature
William Monaco¹, William F.C. Rigby² and Jonathan Jones³, ¹Internal Medicine, Dartmouth-Hitchcock Medical Center, Lebanon, NH, ²Geisel School of Medicine at Dartmouth, Lebanon, NH, ³Rheumatology, Dartmouth-Hitchcock Medical Center, Lebanon, NH
Background/Purpose: Rituximab (RTX) has been associated with late onset neutropenia (LON), defined as an absolute neutrophil count (ANC) < 1.5 x 109/L at least 4 weeks…
Abstract Number: 1555 • 2015 ACR/ARHP Annual Meeting
Geography and the Influence of Comorbidity on the Prevalence of Depression in Patients with Rheumatoid Arthritis,a Study Across Seventeen Countries
Raluca Dumitru¹, Elizabeth M.A. Hensor², Ihsane Hmamouchi³, Paul Emery², Maxime Dougados⁴ and Maya H. Buch⁵, ¹University of Leeds, Leeds Institute of Molecular Medicine and LMBRU, Leeds, United Kingdom, ²Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ³El Ayachi Hospital, Rabat, Morocco, ⁴Service de Rhumatologie B, GHU Cochin, F-75014 France, PARIS, France, ⁵Division of Rheumatic and Musculoskeletal Disease, University of Leeds, Leeds Institute of Molecular Medicine and LMBRU, Leeds, United Kingdom
Background/Purpose: Comorbidities represent a major challenge for patients with rheumatoid arthritis. Depression is one of the most common comorbidities with prevalence up to 38%. Disease…
Abstract Number: 2626 • 2015 ACR/ARHP Annual Meeting
Disease Activity Predicts ABCB1 and ABCG2 Drug-Efflux Transporters Function in Rheumatoid Arthritis (RA) Patients
Yemil Atisha-Fregoso¹, Guadualupe Lima², Virginia Pascual-Ramos³, Juan Jakez-Ocampo⁴, Hilda Fragoso-Loyo⁵, Miguel Baños⁶, Luis Llorente⁷ and Irazú Contreras-Yáñez⁸, ¹Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubiran, Mexico City, Mexico, ²Immunology and Rheumatology, Instituto Nacional de Ciencias Medicas y Nutricion, Mexico City, Mexico, ³Mexican Accreditation Council of Rheumatology, A.C., Mexico City, Mexico, ⁴Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, México, Mexico, ⁵Vasco de Quiroga 15 Col Seccio, INNCMSZ-Departamento de Inmunología y Reumato, Mexico, Mexico, ⁶Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico, Mexico, ⁷Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ⁸Inmunología y Reumatología, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico
Background/Purpose: ABCB1 (P-gp) and ABCG2 (BCRP1) are part of the adenine triphosphate (ATP)-binding cassette transporter proteins. These proteins can modulate inflammatory responses and mediate efflux…
Abstract Number: 605 • 2015 ACR/ARHP Annual Meeting
Monitoring of Epstein Barr Virus, Cytomegalovirus and Varicella Zooster Virus Load in Patients Receiving Tocilizumab for Rheumatoid Arthritis
cindy mourgues¹, cecile henquell², Zuzana Tatar³, Bruno Pereira⁴, cynthia nourisson⁵, Anne Tournadre⁶, Martin Soubrier⁷ and Marion Couderc⁷, ¹puy de dome, CHU gabriel montpied clermont ferrand, clermont ferrand, France, ²virology, CHU gabriel montpied virology, clermont ferrand, France, ³Rheumatology, CHU G.-Montpied, Clermont-Ferrand, France, ⁴Biostatistics unit (DRCI), CHU Clermont-Ferrand, Clermont-Ferrand, France, ⁵rheumatology, chu gabriel montpied, clermont ferrand, France, ⁶Rheumatology, UNH-UMR 1019 INRA University of Auvergne and Rheumatology department CHU Clermont-Ferrand, Clermont-Ferrand, France, ⁷Rheumatology department CHU Clermont-Ferrand, Clermont-Ferrand, France
Background/Purpose: Tocilizumab (TCZ) is an interleukin 6 (IL-6) inhibitor that is used in Rheumatoid Arthritis (RA) treatment (1). Due to the role played by IL-6…
Abstract Number: 1614 • 2015 ACR/ARHP Annual Meeting
The Impact of High Risk Susceptible Gene LILRA3 on Joint Inflammation in Rheumatoid Arthritis
Mengru Liu¹, Yan Du², Jing Zhang¹, Fanlei Hu¹, Li Zheng³, Yingni Li³, Jianping Guo¹ and Z. Li¹, ¹Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing, China, ²Department of Rheumatology and Immunology, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Zhejiang, China, ³Peking University People's Hospital, Beijing, China
Background/Purpose: Leukocyte immunoglobulin-like receptor A3 (LILRA3) is a putatively secreted protein belongs to the leukocyte immunoglobulin-like receptor (LILR) family. Based on our research that LILRA3…
Abstract Number: 2661 • 2015 ACR/ARHP Annual Meeting
Assessing Information Needs for Chronic Disease Management in Rheumatoid Arthritis
Marylou Cardenas-Turanzas¹, Elsa Gonzalez², Maithili Shethia¹, Maria A. Lopez-Olivo³, Pratibha Nayak⁴ and Maria E. Suarez-Almazor³, ¹Department of General Internal Medicine, The University of Texas, MD Anderson Cancer Center, Houston, TX, ²Higher Education Administration, Texas A&M University, Corpus Christi, TX, ³General Internal Medicine, The University of Texas, MD Anderson Cancer Center, Houston, TX, ⁴National Institutes of Health, Atlanta, GA
Background/Purpose: Patients with chronic disease are increasingly using social networking to share experiences about their disease, and receive peer support. As part of an educational…
Abstract Number: 7 • 2015 ACR/ARHP Annual Meeting
Influence of TNF on Anti-Inflammatory Tyrosine-Hydroxylase-Positive Synovial Cells in Rheumatoid Arthritis and Osteoarthritis
Zsuzsa Jenei-Lanzl, Markus Herrmann and Rainer Straub, Laboratory of Experimental Rheumatology and Neuroendocrine Immunology, Department of Internal Medicine, University Hospital Regensburg, Regensburg, Germany
Background/Purpose: In recent studies we demonstrated that catecholamines produced by tyrosine-hydroxylase-positive (TH+) synovial cells are able to mediate anti-inflammatory effects in rheumatoid arthritis (RA).a TNF…
Abstract Number: 608 • 2015 ACR/ARHP Annual Meeting
Safety of Surgery in Patients with Rheumatoid Arthritis Treated By Abatacept: Data from the French Orencia in Rheumatoid Arthritis (ORA) Registry
Augustin Latourte¹, Jacques Gottenberg², Cécile Luxembourger³, Isabelle Pane⁴, Pascal Claudepierre⁵, Pascal Richette¹, Pierre Lafforgue⁶, Philippe Ravaud⁴, BG Combe⁷, Alain G. Cantagrel³, Jean Sibilia⁸, Rene-Marc Flipo⁹, Philippe Gaudin¹⁰, Olivier Vittecoq¹¹, Thierry Schaeverbeke¹², Maxime Dougados¹³, Francis Berenbaum¹⁴, Jérémie Sellam¹⁵, Xavier Mariette¹⁶ and Raphaèle Seror¹⁷, ¹Fédération de Rhumatologie, Hôpital Lariboisière, Assistance Publique-Hôpitaux de Paris, Paris, France, ²Rheumatology, Department of Rheumatology, Strasbourg University Hospital, Strasbourg, France, ³Rheumatology, Centre Hospitalier Universitaire, Toulouse Purpan, Toulouse, France, ⁴Centre de Recherche en Epidémiologie et Statistiques, INSERM U1153, Centre d'Épidémiologie Clinique, Hôpital Hôtel-Dieu, Assistance Publique-Hôpitaux de Paris (AP-HP), Descartes University, Paris, France, ⁵Rheumatology, Université Paris Est Créteil, Créteil, France, ⁶Rheumatology, APHM, Aix Marseille University, Marseille, France, ⁷Rhumatologie, Immuno-Rhumatologie, Hopital Lapeyronie, Montpellier, France, ⁸Department of Rheumatology, Strasbourg University Hospital, Strasbourg, France, ⁹Rheumatology, Hopital R Salengro CHRU, Lille, France, ¹⁰Department of Rheumatology, University Hospital Grenoble, Grenoble, France, ¹¹University Hospital, Rouen, France, ¹²Rheumatology Department, Bordeaux Hospital, Bordeaux, France, ¹³Medicine Faculty, Paris-Descartes University, Paris, UPRES-EA 4058, Cochin Hospital, Rheumatology B, Paris, France, ¹⁴Rheumatology, Inserm UMRS_938, AP-HP, St Antoine Hospital, Univ Paris 06, DHU i2B, Paris, France, ¹⁵Rheumatology and Inserm UMRS_938, AP-HP, St Antoine Hospital, Univ Paris 06, DHU i2B, Paris, France, ¹⁶Université Paris-Sud, AP-HP, Hôpitaux Universitaires Paris-Sud, Paris, France, ¹⁷Rheumatology, AP-HP Bicêtre Hospital / Paris-Sud University, Le Kremlin-Bicêtre, France
Background/Purpose: The aim of this study was to investigate the frequency and risk factors of postoperative complications in rheumatoid arthritis (RA) patients treated with abatacept…
Abstract Number: 1635 • 2015 ACR/ARHP Annual Meeting
Development of New Bioassay System Measuring Inhibitory Strength of IL-6/STAT3 Signal Under Tocilizumab Treatment in Rheumatoid Arthritis Patients
Shuntaro Saito¹, Katsuya Suzuki¹, Kunihiro Yamaoka¹ and Tsutomu Takeuchi², ¹Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ²Keio University School of Medicine, Tokyo, Japan
Background/Purpose: Tocilizumab (TCZ) is a IL-6 receptor blockade, administered intravenously every 4 weeks and efficiently inhibits IL-6/STAT3 signaling pathway. We have previously reported the usefulness…
Abstract Number: 2664 • 2015 ACR/ARHP Annual Meeting
Flares Occur Frequently in RA Patients Undergoing Arthroplasty
Susan M. Goodman¹, Rivka Friedlander², Caroline Figgie², Anh Hoang¹, Kathleen Andersen³, Alessandra B. Pernis⁴, Cristina T. Rozo⁵, Edward F. DiCarlo⁶, Mark P. Figgie⁷, Laura T. Donlin⁸ and VP Bykerk³, ¹Rheumatology, Hospital for Special Surgery, New York, NY, ²Research, Hospital for Special Surgery, New York, NY, ³Hospital for Special Surgery, New York, NY, ⁴Autoimmunity & Inflammation, Hospital for Special Surgery, New York, NY, ⁵535 East 70th Street, Hospital for Special Surgery, New York, NY, ⁶Laboratory Medicine, Hospital for Special Surgery, New York, NY, ⁷Orthopaedics, Hospital for Special Surgery, New York, NY, ⁸Arthritis and Tissue Degeneration Program and the David Z. Rosensweig Genomics Research Center, Hospital for Special Surgery, New York, NY
Background/Purpose: RA patients are at risk for disease worsening (flare) after joint surgery, as medication is withdrawn to mitigate infection risk. We aimed to describe…
Abstract Number: 48 • 2015 ACR/ARHP Annual Meeting
Polypharmacy Is a Predictor of Hospitalisation in Patients with Rheumatoid Arthritis
Maria Filkova¹, Joao Carvalho¹, Sam Norton², David L. Scott¹, Tim Mant³, Andrew P. Cope¹, Mariam Molokhia⁴ and James Galloway¹, ¹Academic Department of Rheumatology, King´s College London, London, United Kingdom, ²Department of Psychological Medicine, King´s College London, London, United Kingdom, ³Quintiles Drug Research Unit at Guy's Hospital, London, London, United Kingdom, ⁴Division of Health and Social Care Research, King´s College London, London, United Kingdom
Background/Purpose: Multimorbidity is a major problem in rheumatoid arthritis (RA) but is difficult to measure. Polypharmacy (PP) - co-prescribing an individual multiple medications – is…
Abstract Number: 615 • 2015 ACR/ARHP Annual Meeting
Rituximab Non Responders Fail to Down Regulated CD19 on Naive B Cells
Hans-Peter Brezinschek¹, Florentine Fürst-Moazedi¹, Sonja Kielhauser², Martin Stradner³ and Winfried Graninger⁴, ¹Internal Medicine/Division of Rheumatology, Medical University Graz, Graz, Austria, ²Internal Medicine/Division of Rheumatology and Immunology, Medical University Graz, Graz, Austria, ³Department of Rheumatology and Immunology, Medical University Graz, Graz, Austria, ⁴Rheumatology and Immunology, Medical University of Graz, Graz, Austria
Background/Purpose: CD19 is a membrane glycoprotein of the immunoglobulin superfamily and part of the hetero-oligomeric complex comprising the complement receptor type 2, which positively regulates…
Abstract Number: 1639 • 2015 ACR/ARHP Annual Meeting
Clinical Outcomes for Rheumatoid Arthritis Patients Receiving Tofacitinib Monotherapy in the Open-Label Long-Term Extension over 6 Years
Roy Fleischmann¹, Yusuf Yazici², Jürgen Wollenhaupt³, Lisy Wang⁴, Anna Maniccia⁵, Kenneth Kwok⁴, Liza Takiya⁵ and Ronald van Vollenhoven⁶, ¹Rheumatology, Metroplex Clinical Research Center, Dallas, TX, ²New York University Hospital for Joint Diseases, New York, NY, ³Teaching Hospital of the University of Hamburg, Schoen-Klinik Hamburg-Eilbek, Hamburg, Germany, ⁴Pfizer Inc, Groton, CT, ⁵Pfizer Inc, New York, NY, ⁶The Karolinska Institute, Stockholm, Sweden
Background/Purpose: Treatment options delivering sustained efficacy when given as monotherapy in RA are limited.1 Tofacitinib is an oral Janus kinase inhibitor for the treatment of…
Abstract Number: 2680 • 2015 ACR/ARHP Annual Meeting
Severity of Morning Stiffness Is Associated More Strongly with Disease Activity in Patients with Rheumatoid Arthritis
Belén Barrios¹, Rafael Chaparro del Moral², Oscar Luis Rillo², Silvia Beatriz Papasidero¹, María Alejandra Medina², Sergio Paira³ and Carolina Sandobal⁴, ¹Rheumatology Department, Hospital General de Agudos Dr. E. Tornú, Buenos Aires, Argentina, ²Rheumatology Section, Hospital General de Agudos Dr. E. Tornú, Buenos Aires, Argentina, ³Rheumatology, Hospital Jose Maria Cullen, Santa Fe, Argentina, ⁴Hospital Jose Maria Cullen, Santa Fe, Argentina
Morning stiffness (MS) is a complex symptom involving pain and functional limitation. It is not included in the ACR/EULAR 2010 classification criteria for rheumatoid arthritis…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].